SAN DIEGO, May 31, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will host its third annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:00 am Pacific Time (12:00 pm Eastern Time), Monday, June 12, 2023.
Francis deSouza, Chief Executive Officer, Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, Aimee Hoyt, Chief People Officer, Phil Febbo, M.D., Chief Medical Officer, John Frank, Chief Public Affairs Officer, and Sharon Vidal, Head of Corporate Social Responsibility, will be joined by Salli Schwartz, Vice President of Investor Relations for a presentation, fireside chat, and Q&A session for investors, analysts, and other interested parties regarding Illumina's ESG strategy and action plans.
Conference Call Details
The webcast will begin at 9:00 am Pacific Time (12:00pm Eastern Time) on Monday, June 12, 2023. Interested parties may register and access the live event through the Investor Info section of Illumina's website at investor.illumina.com or directly at Illumina Virtual ESG Investor Event. Attendees may submit questions in advance on the registration page.
To ensure timely connection, please join the webcast at least ten minutes before the scheduled start. A replay of the webcast will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, TikTok and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David McAlpine
+1.347.327.1336
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$99.97 |
| Daily Change: | 2.74 2.82 |
| Daily Volume: | 1,202,205 |
| Market Cap: | US$15.370B |
October 15, 2025 September 23, 2025 September 03, 2025 August 19, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load